Types of Regulatory Submissions in Clinical Research

What Are Regulatory Submissions in Clinical Research?

Regulatory submissions are formal filings and reports that sponsors provide to regulatory authorities across every phase of a study. They are not limited to the initial approval to begin testing. A sponsor files submissions before a trial starts, throughout its conduct, and again when the study closes or moves toward a marketing decision.

“Application” and “submission” are overlapping terms, but they are used differently:

• An application is generally a formal request for authorization or approval.
• A submission can refer more broadly to information or documentation filed with a regulatory authority, including an initial application, amendment, report, or safety filing.

Sponsors that treat regulatory affairs in clinical trials as a one-time hurdle instead of a continuous process tend to fall behind once the trial is underway.

What Are Different Types of Regulatory Submissions in Clinical Trials?

All types of regulatory submissions answer a specific question for the reviewing authority: what is being tested, what has changed, what went wrong, or what the final data shows.

Initial Trial Applications:

Sponsors generally submit an Investigational New Drug (IND) application when an IND is required for a drug investigation in the United States. Other jurisdictions use different regulatory frameworks and terminology for authorization to conduct clinical trials. In the European Union, Clinical Trial Applications (CTA) are submitted through the Clinical Trials Information System (CTIS).

According to the FDA, sponsors must wait 30 calendar days after submitting an IND before initiating a trial to give the agency time to flag any safety concerns. This filing includes preclinical data, manufacturing information, and the proposed clinical protocol.

Protocol and Trial Amendments:

Trials rarely run exactly as designed on paper. An inclusion criterion might prove too restrictive, or a new safety signal might require a design change. Depending on the nature and significance of the change, a protocol amendment may need to be submitted to the regulatory authority and the relevant ethics body before implementation.

How rigorously a sponsor approaches clinical trial site selection at the outset often determines how many amendments a protocol ends up needing later.

Safety Submissions:

Serious Adverse Event (SAE) and Suspected Unexpected Serious Adverse Reaction (SUSAR) reports carry some of the strictest timelines in clinical research. They require notification within 7 to 15 days depending on severity and jurisdiction.

Many authorities also require a Development Safety Update Report (DSUR), which is a periodic safety report used in the ICH framework and accepted by FDA to fulfill IND annual-reporting requirements in applicable circumstances. Managing this reporting obligation accurately is the core function of pharmacovigilance and drug safety monitoring within any active trial.

Periodic and Ongoing Reports:

Sponsors with an active IND must submit an annual report within 60 days of the anniversary date on which the IND went into effect. These reports keep the regulatory authority informed without requiring a new application for every incremental update.

Information Amendments:

These amendments provide important information about an IND that doesn’t fall within the categories of protocol amendments, safety reports, or annual reports.

New toxicology data, updated chemistry, manufacturing, and controls (CMC) information, or other technical findings typically prompt this kind of filing. Sponsors submit these amendments as needed throughout the life of the IND, keeping the regulatory authority current without triggering the stricter timelines that govern safety or annual reporting.

Investigator’s Brochure and Information Updates:

The Investigator’s Brochure summarizes everything known about a drug’s safety and efficacy at a given point. As new information becomes available, sponsors update the Investigator’s Brochure when required and provide the revised version to investigators and relevant regulatory or ethics bodies in accordance with applicable requirements.

Marketing Applications:

When the sponsor has sufficient evidence to support an application for marketing authorization, it may submit an NDA, BLA, MAA, or another applicable marketing application depending on the product and jurisdiction.

This submission compiles the clinical, nonclinical, quality, and other information required by the applicable regulatory framework.

How Do Regulatory and Ethics Submissions Differ?

Ethics submissions and regulatory submission requirements for clinical trials serve different oversight functions, although the same study change may require review by both.

Treating these as one filing type is a common but avoidable mistake. A protocol change may require review by both the regulatory authority and the IRB / Ethics Committee, depending on the nature of the change and applicable requirements. Each body evaluates the change from a different oversight perspective.

Regulatory Submission Requirements for Clinical Trials

Meeting submission requirements demands more than just filling out a form correctly.

Authorities expect:

• Standardized electronic formatting, typically through the eCTD (electronic Common Technical Document) structure.
• Complete and traceable source documentation supporting every data point.
• Compliance with Good Clinical Practice, as outlined in the ICH E6(R3) guideline.
• Internal quality assurance review before any document leaves the sponsor’s hands.

This is where the role of quality assurance in clinical trials becomes central, since QA functions as the last checkpoint before any submission reaches a regulator.

Clinical Research Regulatory Affairs Process

Regulatory submissions are one output of a broader regulatory affairs process that spans the entire clinical trial management process, from initial IND filing through final closeout. A regulatory affairs team can track submission obligations against the trial calendar, coordinate with clinical operations, and maintain the documentation needed to demonstrate compliance.

Sponsors that lack dedicated regulatory affairs support often discover gaps only when a deadline has already passed. Structuring this function early, whether in-house or through a CRO partner, is one of the clearest ways to keep a trial on schedule.

How to Prepare Regulatory Submissions for Clinical Trials

Preparing a submission starts long before the filing deadline. A dependable process for preparing regulatory submissions includes:

1. Building a submission timeline against every trial milestone.
2. Assembling source documentation as it is generated rather than reconstructing it later.
3. Cross-checking every submission against the applicable source documents.
4. Routing each document through internal regulatory and QA review before filing.
5. Tracking versioning and submission status through a centralized system.

A system that simplifies regulatory submissions and document management gives regulatory teams a single source of truth for what has been filed, what is pending, and what documentation supports each submission. Ongoing clinical trial monitoring can also help identify documentation and compliance issues early enough for the regulatory team to address them within applicable reporting timelines.

Final Remarks

Regulatory submissions are a critical part of keeping a clinical trial compliant and moving through the regulatory lifecycle. Sponsors that build submission management into their trial planning from day one can reduce avoidable delays and last-minute compliance gaps.

Minerva Research Solutions supports sponsors through every stage of this process, from initial IND strategy to ongoing safety reporting, supported by a team focused on clinical research and regulatory operations.